{"gene":"ACKR3","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2005,"finding":"CXCL12/SDF-1 binds to and signals through RDC1 (renamed CXCR7/ACKR3) with high affinity (apparent KD ~0.4 nM), promoting receptor internalization and chemotactic signals in CXCR4-negative cells expressing RDC1, establishing RDC1 as a bona fide CXCL12 receptor in T lymphocytes.","method":"Radioligand binding assay, chemotaxis assay with anti-RDC1 antibody blockade, receptor internalization assay in CXCR4-negative cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (binding kinetics, functional chemotaxis, internalization) in a single foundational paper; widely replicated","pmids":["16107333"],"is_preprint":false},{"year":2009,"finding":"CXCR7 forms constitutive heterodimers with CXCR4 (as efficiently as homodimers), does not itself trigger Gαi-protein-dependent signaling despite constitutive interaction with Gαi proteins, and impairs CXCR4-promoted Gαi-protein activation and calcium responses when co-expressed, identifying CXCR4/CXCR7 heterodimers as distinct functional units that modulate CXCL12 signaling.","method":"BRET/FRET energy transfer assays for protein–protein interactions, G protein signaling assays, calcium flux assays, primary T cell co-expression studies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal BRET/FRET assays plus functional G-protein and calcium readouts; moderate replication","pmids":["19380869"],"is_preprint":false},{"year":2012,"finding":"CXCR7 is constitutively ubiquitinated, and this ubiquitination is required for correct trafficking from and to the plasma membrane; CXCL12 treatment causes reversible de-ubiquitination. Internalization depends on both β-arrestin and Ser/Thr residues at the C-terminus, and C-terminal Lys residues are essential for surface delivery.","method":"Mutagenesis of C-terminal Ser/Thr and Lys residues, ubiquitination assays, internalization/recycling assays, β-arrestin depletion","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 — direct mutagenesis plus functional trafficking assays with multiple controls in a single study","pmids":["22457824"],"is_preprint":false},{"year":2012,"finding":"The C-terminal intracellular tail of CXCR7 controls receptor localization (wild-type receptor localizes predominantly to intracellular vesicles), constitutive internalization, ligand-dependent β-arrestin-2 recruitment, chemokine scavenging, and CXCL12-stimulated ERK1/2 activation; dynamin-dependent internalization facilitates β-arrestin-2 association and ERK1/2 signaling.","method":"Carboxy-terminus deletion mutants, firefly luciferase complementation for β-arrestin-2 recruitment, dynamin inhibition, ERK1/2 phosphorylation assays, CXCL12 scavenging assays","journal":"The international journal of biochemistry & cell biology","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution with multiple deletion mutants, orthogonal assays for trafficking, signaling, and scavenging","pmids":["22300987"],"is_preprint":false},{"year":2014,"finding":"CXCR7 acts as a decoy/scavenger receptor for adrenomedullin (AM), controlling AM bioavailability and downstream GPCR-mediated cardiac and lymphatic vascular development; Cxcr7−/− mice show gain-of-function cardiac and lymphatic phenotypes rescued by genetic depletion of the adrenomedullin ligand.","method":"Genetic mouse knockout (Cxcr7−/−), adrenomedullin ligand double-knockout rescue epistasis, cardiac/lymphatic phenotyping","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — rigorous genetic epistasis with double-mutant rescue establishing ligand–receptor relationship in vivo","pmids":["25203207"],"is_preprint":false},{"year":2019,"finding":"ACKR3 phosphorylation (but not β-arrestin) is essential for its function as a CXCL12 scavenger controlling interneuron migration; phosphorylation-deficient ACKR3 mice exhibit major interneuron migration defects accompanied by excess CXCL12, lysosomal CXCR4 degradation, and loss of CXCR4 responsiveness, demonstrating that ACKR3 sequesters CXCL12 to prevent over-activation and subsequent loss of CXCR4.","method":"Phosphorylation-deficient and β-arrestin-deficient knock-in mice, in vivo interneuron migration assays, CXCL12 level measurements, CXCR4 degradation assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — clean genetic models (phospho-deficient and β-arrestin KO) with defined cellular phenotype; mechanistic dissection of phosphorylation vs. β-arrestin roles","pmids":["30726732"],"is_preprint":false},{"year":2020,"finding":"ACKR3/CXCR7 is a broad-spectrum scavenger receptor for opioid peptides (especially enkephalins and dynorphins), functioning as a negative regulator of opioid peptide availability for classical opioid receptors; an ACKR3-selective competitor peptide (LIH383) potentiates opioid peptide activity toward classical receptors in rat brain.","method":"Radioligand binding, β-arrestin recruitment assays, in vitro scavenging assays, rat brain ex vivo pharmacology with LIH383 competitor peptide","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal in vitro assays plus in vivo pharmacological validation with selective tool compound","pmids":["32561830"],"is_preprint":false},{"year":2014,"finding":"Endothelial CXCR7 regulates circulating CXCL12 levels; genetic deletion or pharmacological inhibition of CXCR7 causes pronounced increases in plasma CXCL12 and impairs leukocyte migration toward local CXCL12 sources; CXCR7 protein is expressed primarily on venule endothelium and arteriole smooth muscle cells in humans and mice.","method":"CXCR7 genetic knockout mice, pharmacological inhibition, ELISA for plasma CXCL12, competitive binding assay, flow cytometry, immunohistochemistry with CXCR7+/lacZ reporter mice","journal":"Immunology","confidence":"High","confidence_rationale":"Tier 2 — complementary genetic and pharmacological approaches with quantitative plasma CXCL12 measurement and reporter mouse localization","pmids":["24116850"],"is_preprint":false},{"year":2019,"finding":"CXCR7 activates MAPK/ERK signaling through β-arrestin 2-dependent, ligand-independent mechanisms in prostate cancer, driving enzalutamide resistance; AR directly represses CXCR7 by binding an enhancer 110 kb downstream of the gene.","method":"Transcriptome analysis, ChIP assay for AR binding, β-arrestin 2 depletion, ERK phosphorylation assays, in vitro and in vivo CRPC growth assays, patient specimen analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — ChIP for AR direct binding, β-arrestin-dependent ERK signaling demonstrated by depletion, in vitro/in vivo confirmation","pmids":["30952632"],"is_preprint":false},{"year":2009,"finding":"CXCR7 increases cell-associated CXCL12 to a significantly greater extent than CXCR4, consistent with a scavenging/internalization function; CXCL12 fused to Gaussia luciferase activates CXCR4-dependent signaling comparably to unfused CXCL12.","method":"Bioluminescent CXCL12-Gaussia luciferase fusion protein binding assay, multiwell plate chemokine uptake quantification, CXCR4 signaling assays","journal":"BioTechniques","confidence":"Medium","confidence_rationale":"Tier 2 — direct quantitative assay but single lab, single paper","pmids":["19594447"],"is_preprint":false},{"year":2011,"finding":"CXCR7 is required for semilunar cardiac valve development; Cxcr7 germline deletion causes aortic and pulmonary valve stenosis with increased mesenchymal cell proliferation and elevated phospho-Smad1/5/8 (BMP signaling); Tie2-Cre conditional knockout recapitulates the phenotype, implicating endocardial cell CXCR7 function.","method":"Germline and Tie2-Cre conditional knockout mice, histological phenotyping, phospho-Smad1/5/8 immunostaining","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic loss-of-function with conditional rescue identifying cell-type specificity; BMP pathway link is correlative","pmids":["21246655"],"is_preprint":false},{"year":2013,"finding":"CXCR7 participates in CXCL12-induced cycling and survival of human CD34+ hematopoietic stem/progenitor cells via β-arrestin 2-dependent Akt activation; β-arrestin 2 translocates to the nucleus after CXCL12 treatment in a manner requiring both CXCR7 and CXCR4, and β-arrestin silencing reduces Akt activation.","method":"CXCR7 blocking antibody, β-arrestin 2 colocalization/nuclear translocation imaging, siRNA silencing of β-arrestins, Akt phosphorylation assays, colony formation and cell cycle assays in primary human CD34+ cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in primary human cells; single lab","pmids":["24277075"],"is_preprint":false},{"year":2014,"finding":"Lhx6 transcription factor directly binds an intronic CXCR7 enhancer in vivo, and CXCR7 regulates laminar positioning of MGE-derived cortical interneurons in neonatal cortex, as shown by MGE complementation/transplantation rescue assays.","method":"ChIP for Lhx6 binding at CXCR7 enhancer, in vivo MGE complementation/transplantation assay, interneuron lamination phenotyping in Lhx6−/− mice","journal":"Neuron","confidence":"Medium","confidence_rationale":"Tier 2 — direct ChIP binding plus in vivo transplantation rescue; single paper","pmids":["24742460"],"is_preprint":false},{"year":2014,"finding":"Dickkopf-3 (Dkk3) physically binds CXCR7 with high affinity (Kd ~14 nmol/L) and triggers ERK1/2, PI3K/AKT, Rac1, and RhoA signaling to drive vascular progenitor cell migration; CXCR7 blocking antibodies impair stem/progenitor cell recruitment into tissue-engineered vessel grafts.","method":"Co-immunoprecipitation, saturation binding assay, overexpression/knockdown functional migration assays, in vivo tissue-engineered vessel graft model with CXCR7 antibody blockade","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2–3 — co-IP plus saturation binding establishes interaction; signaling and in vivo functional follow-up; single lab","pmids":["29980568"],"is_preprint":false},{"year":2016,"finding":"HHV-8-encoded vCCL2/vMIP-II is a high-affinity ligand for ACKR3, acting as a partial agonist that induces β-arrestin recruitment, reduces surface ACKR3 levels, delivers receptor to endosomes, and reduces vCCL2-triggered MAP kinase and PI3K/Akt signaling through other chemokine receptors.","method":"β-arrestin recruitment assay, receptor surface level measurement by flow cytometry, endosomal trafficking imaging, MAP kinase and PI3K/Akt signaling assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays; single lab demonstrating novel ligand–receptor interaction","pmids":["27238288"],"is_preprint":false},{"year":2021,"finding":"A single cluster of phosphorylated residues on the ACKR3 C-tail (particularly T352 and S355) determines β-arrestin1 recruitment; GRK2 and GRK3 phosphorylate ACKR3 and are key for β-arrestin recruitment and receptor internalization; ACKR3 can internalize independently of β-arrestins via alternative pathways; upon activation ACKR3 internalizes and recycles to the cell membrane.","method":"BRET/FRET-based sensors in HEK293T cells, phosphorylation site mutagenesis, GRK co-expression/knockdown, receptor internalization and trafficking assays","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 1–2 — mutagenesis combined with BRET/FRET sensors; single lab but comprehensive mechanistic dissection","pmids":["33799570"],"is_preprint":false},{"year":2023,"finding":"CXCR7 lacks G-protein coupling while maintaining robust β-arrestin recruitment (predominantly via GRK5/6); CXCR7 and CXCR4 induce distinct β-arrestin conformations when activated by the same agonist CXCL12; CXCR7, unlike CXCR4, fails to activate ERK1/2 MAP kinase; a single phosphorylation site on CXCR7 is key for β-arrestin recruitment and endosomal localization.","method":"Comprehensive transducer-coupling characterization, βarr conformation BRET sensors, GRK isoform-specific assays, phosphorylation site mutagenesis, ERK1/2 assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — comprehensive reconstitution with multiple sensors and mutagenesis; rigorous mechanistic dissection of biased signaling","pmids":["37558722"],"is_preprint":false},{"year":2022,"finding":"Megakaryocyte/platelet-specific deletion of ACKR3 enhances platelet activation and thrombosis in vitro and in vivo; ACKR3 ligation with specific agonists inhibits platelet activation, thrombus formation, and attenuates tissue injury in ischemic myocardium and brain; ACKR3 agonism favors antithrombotic lipids (DGLA, 12-HETrE) over prothrombotic lipids, and 12-HETrE coordinates with Gαs-coupled prostacyclin receptor to trigger cAMP/PKA-mediated platelet inhibition.","method":"Platelet-specific Ackr3 conditional knockout mice, in vitro platelet activation assays, in vivo thrombosis and ischemia-reperfusion models, targeted and untargeted lipidomics (micro-UHPLC-ESI-MS/MS)","journal":"Nature communications / Blood","confidence":"High","confidence_rationale":"Tier 2 — cell-specific genetic KO with defined phenotype plus mechanistic lipidomics and pharmacological agonist validation in vivo","pmids":["35383158","34905596"],"is_preprint":false},{"year":2022,"finding":"Arterial endothelial ACKR3 promotes atherosclerosis by mediating immune cell adhesion to vascular endothelium through MAPK (ERK1/2) and NF-κB p65 pathways; smooth muscle cell or hematopoietic ACKR3 deficiency does not impact atherosclerosis.","method":"Apoe−/− mice with endothelial- or smooth muscle cell-specific Ackr3 deletion, atherosclerosis quantification, adhesion molecule expression, ERK1/2 and NF-κB p65 phosphorylation assays, ACKR3 silencing in human coronary artery endothelial cells","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-type-specific genetic deletion with pathway mechanistic follow-up; single lab","pmids":["35674847"],"is_preprint":false},{"year":2021,"finding":"PAMP-12 (proadrenomedullin N-terminal 20 peptide processed form) is a high-potency agonist for ACKR3, inducing β-arrestin recruitment and efficient receptor internalization without activating G protein or ERK signaling, identifying ACKR3 as a regulator of PAMP-12 availability for its primary receptor MrgX2.","method":"β-arrestin recruitment assay, G protein signaling assay, ERK assay, receptor internalization assay, comparison with ADM and CGRP family members with/without RAMPs","journal":"ACS pharmacology & translational science","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal functional assays; single lab; novel ligand identification","pmids":["33860204"],"is_preprint":false},{"year":2019,"finding":"CXCR7 activates MAPK-ERK signaling via β-arrestin (not G-protein) to drive acquired resistance to EGFR TKIs in NSCLC; depletion of CXCR7 inhibits the MAPK pathway, attenuates EGFR TKI resistance, and induces mesenchymal-to-epithelial transition.","method":"CXCR7 depletion by siRNA/shRNA, ERK phosphorylation assays, EGFR TKI resistance models in vitro, patient specimen CXCR7 expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional depletion with defined signaling readout; single lab; mechanistic β-arrestin link inferred","pmids":["31273063"],"is_preprint":false},{"year":2018,"finding":"MIF (macrophage migration inhibitory factor) is identified as a ligand for CXCR7, activating AKT signaling and inducing cell-cycle gene expression; AR directly represses CXCR7 expression (shown by CRISPR/Cas9 editing); the MIF/CXCR7/AKT pathway drives CRPC growth independent of CXCL12/CXCR4.","method":"CRISPR/Cas9-mediated AR binding site deletion, ligand binding assay for MIF-CXCR7, AKT phosphorylation assays, gene expression profiling, in vivo xenograft studies","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR validation of AR binding plus functional ligand identification; single lab","pmids":["30224544"],"is_preprint":false},{"year":2016,"finding":"CXCR7 transactivates EGFR in a β-arrestin-2-independent (G-protein-independent) manner; β-arrestin-2 acts as a negative regulator (tumor suppressor) of CXCR7/Src/EGFR-mediated mitogenic signaling; β-arrestin-2 depletion increases Src phosphorylation, EGFR Tyr-1110 phosphorylation, ERK1/2 activation, and nuclear EGFR translocation.","method":"β-arrestin-2 shRNA knockdown, cDNA knock-in, proximity ligation assay for CXCR7-EGFR colocalization, phosphorylation assays (Src, EGFR, ERK1/2, Akt), nuclear EGFR translocation imaging","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple signaling assays with knockdown; single lab; mechanistic β-arrestin-2 role defined","pmids":["26921391"],"is_preprint":false},{"year":2014,"finding":"CXCR7 interacts with EGFR in breast cancer cells, and β-arrestin-2 acts as a scaffold to enhance CXCR7-dependent activation of EGFR after EGF stimulation; CXCR7 depletion reduces EGFR phosphorylation at Tyr1110 and ERK1/2 phosphorylation.","method":"In situ proximity ligation assay (PLA) for CXCR7-EGFR colocalization in cancer tissues/cells, siRNA knockdown of CXCR7 and β-arrestin2, Western blotting for phospho-EGFR and phospho-ERK1/2","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 — PLA establishes proximity plus functional signaling readout; single lab","pmids":["25168820"],"is_preprint":false},{"year":2019,"finding":"CXCR7 promotes melanoma proliferation via β-arrestin2-dependent Src kinase phosphorylation; CXCR7-Src axis stimulates eIF4E phosphorylation, accelerating HIF-1α translation and VEGF secretion to drive angiogenesis.","method":"CXCR7 knockout, Src kinase inhibitor PP1, β-arrestin2 siRNA, eIF4E and HIF-1α western blotting, VEGF ELISA, in vivo xenograft","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 — genetic knockout plus pharmacological inhibition with defined pathway; single lab","pmids":["30804329"],"is_preprint":false},{"year":2014,"finding":"CXCR7 promotes oligodendroglial precursor cell maturation and myelin expression via CXCL12 stimulation; pharmacological inhibition of CXCR7 blocks CXCL12-dependent oligodendrocyte maturation, while CXCR7 antagonism in vivo augments OPC proliferation and increases mature oligodendrocyte numbers in demyelinated lesions, requiring CXCR4 co-activation.","method":"Pharmacological CXCR7 inhibition in primary OPC cultures, CXCR7 antagonist in cuprizone demyelination model in vivo, phospho-S339-CXCR4 antibody, CXCR4 antagonist epistasis","journal":"The Journal of experimental medicine / Annals of neurology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo pharmacological inhibition with CXCR4 epistasis; two independent papers","pmids":["24733828","21154415"],"is_preprint":false},{"year":2023,"finding":"CXCR7 activates the Hippo/YAP axis via Gαq/11 and Rho GTPase signaling, causing YAP dephosphorylation and nuclear accumulation in gastric cancer; YAP in turn binds the CXCR7 promoter to transcriptionally upregulate CXCR7, forming a positive feedback loop.","method":"ChIP assay for YAP binding at CXCR7 promoter, Gαq/11 and Rho GTPase inhibition, YAP phosphorylation/localization assays, pharmacological CXCR7 inhibition (ACT-1004-1239), in vivo xenograft model","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP for YAP binding plus mechanistic pathway dissection; single lab","pmids":["37950281"],"is_preprint":false},{"year":2017,"finding":"TGF-β1 upregulates CXCR7 expression via Smad2/3-dependent signaling in endothelial cells; overexpressed CXCR7 attenuates TGF-β1-induced endothelial-to-mesenchymal transition by inhibiting the Jag1-Notch pathway.","method":"Smad2/3 inhibition, CXCR7 overexpression and knockdown in endothelial cells, EndMT marker assays, Jag1-Notch pathway analysis, in vivo mouse lung fibrosis model","journal":"Molecular bioSystems","confidence":"Medium","confidence_rationale":"Tier 2–3 — Smad2/3-dependent transcriptional mechanism plus functional EndMT assays; single lab","pmids":["28820530"],"is_preprint":false}],"current_model":"ACKR3/CXCR7 is an atypical chemokine receptor that binds CXCL12, CXCL11, adrenomedullin-related peptides, opioid peptides, and viral chemokines with high affinity but does not couple to G proteins; instead it signals constitutively and upon ligand activation through β-arrestin recruitment (facilitated by GRK2/3/5/6-mediated C-tail phosphorylation) and dynamin-dependent internalization to scavenge extracellular chemokines, modulate plasma CXCL12 levels, regulate CXCR4 activity through direct heterodimerization, activate ERK via β-arrestin scaffolding, control cardiac valve and lymphatic development, guide cortical interneuron migration, and inhibit platelet activation through a lipid-mediated cAMP/PKA pathway."},"narrative":{"teleology":[{"year":2005,"claim":"The orphan receptor RDC1 was identified as a second high-affinity CXCL12 receptor (renamed CXCR7), resolving whether CXCR4 was the sole receptor for this chemokine and opening the question of how two receptors partition CXCL12 signaling.","evidence":"Radioligand binding, chemotaxis, and internalization assays in CXCR4-negative T cells","pmids":["16107333"],"confidence":"High","gaps":["Whether CXCR7 signals through canonical G-protein pathways was untested","Physiological role in vivo unknown"]},{"year":2009,"claim":"CXCR7 was shown to heterodimerize constitutively with CXCR4 and to attenuate CXCR4-Gαi coupling and calcium signaling, establishing that CXCR7 modulates CXCL12 responses indirectly through receptor–receptor interactions rather than canonical G-protein signaling.","evidence":"BRET/FRET dimerization assays, G-protein activation and calcium flux assays in co-expressing cells and primary T cells","pmids":["19380869"],"confidence":"High","gaps":["Signaling pathway downstream of CXCR7 itself unresolved","Scavenging capacity versus CXCR4 not directly compared"]},{"year":2009,"claim":"Quantitative comparison showed CXCR7 accumulates more cell-associated CXCL12 than CXCR4, supporting a predominant scavenger function.","evidence":"Bioluminescent CXCL12-Gaussia luciferase uptake assay","pmids":["19594447"],"confidence":"Medium","gaps":["Single assay system without in vivo validation","Internalization kinetics and recycling not characterized"]},{"year":2011,"claim":"Genetic deletion revealed CXCR7 is required for semilunar cardiac valve development, with loss-of-function causing valve stenosis and elevated BMP signaling, establishing the first in vivo developmental requirement.","evidence":"Germline and Tie2-Cre endocardial-specific Cxcr7 knockout mice with phospho-Smad1/5/8 immunostaining","pmids":["21246655"],"confidence":"Medium","gaps":["BMP pathway link is correlative—direct molecular mechanism connecting CXCR7 to Smad1/5/8 undefined","Ligand mediating valve phenotype unidentified"]},{"year":2012,"claim":"The C-terminal tail was defined as the molecular determinant controlling CXCR7 constitutive internalization, β-arrestin-2 recruitment, ERK activation, ubiquitination-dependent trafficking, and chemokine scavenging, establishing β-arrestin-biased signaling as the principal transduction mechanism.","evidence":"C-tail deletion/point mutants, ubiquitination assays, dynamin inhibition, β-arrestin depletion, ERK phosphorylation, and CXCL12 scavenging assays","pmids":["22300987","22457824"],"confidence":"High","gaps":["Specific phosphorylation sites and responsible kinases not yet mapped","Whether β-arrestin is essential or dispensable for internalization unclear"]},{"year":2014,"claim":"Genetic epistasis demonstrated that CXCR7 scavenges adrenomedullin in addition to CXCL12, establishing it as a multi-ligand decoy receptor controlling cardiac and lymphatic vascular development through ligand removal rather than signal transduction.","evidence":"Cxcr7−/− and Cxcr7−/−;Adm+/− double-knockout rescue in mice with cardiac/lymphatic phenotyping","pmids":["25203207"],"confidence":"High","gaps":["Structural basis for adrenomedullin binding versus CXCL12 binding unknown","Whether adrenomedullin scavenging occurs in adult tissues untested"]},{"year":2014,"claim":"CXCR7 was placed in neural circuit development: endothelial CXCR7 controls plasma CXCL12 gradients for leukocyte migration, while neuronal CXCR7 directs cortical interneuron laminar positioning under Lhx6 transcriptional control, broadening its physiological scope beyond vascular biology.","evidence":"CXCR7 knockout mice with plasma CXCL12 ELISA, CXCR7-lacZ reporter immunohistochemistry; ChIP for Lhx6 at CXCR7 enhancer, MGE transplantation rescue in Lhx6−/− mice","pmids":["24116850","24742460"],"confidence":"High","gaps":["Whether scavenging or signaling mediates interneuron guidance not dissected","Other transcriptional regulators of CXCR7 in neurons unknown"]},{"year":2014,"claim":"CXCR7 was found to interact with EGFR via β-arrestin-2 scaffolding, enhancing EGFR phosphorylation and ERK signaling in breast cancer, revealing a crosstalk mechanism with receptor tyrosine kinases.","evidence":"Proximity ligation assay for CXCR7-EGFR, siRNA knockdown of CXCR7 and β-arrestin-2, phospho-EGFR/ERK Western blots","pmids":["25168820"],"confidence":"Medium","gaps":["Direct versus indirect interaction not resolved","Whether EGFR crosstalk occurs in non-cancer contexts unknown"]},{"year":2016,"claim":"HHV-8 vCCL2 was identified as a high-affinity viral partial agonist of ACKR3 that triggers β-arrestin recruitment and receptor internalization, demonstrating viral exploitation of the scavenging pathway.","evidence":"β-arrestin recruitment, receptor surface quantification, endosomal trafficking, and signaling assays","pmids":["27238288"],"confidence":"Medium","gaps":["In vivo relevance during HHV-8 infection not tested","Structural basis for partial agonism unknown"]},{"year":2019,"claim":"Phosphorylation-deficient ACKR3 knock-in mice dissociated phosphorylation from β-arrestin dependence in vivo: C-tail phosphorylation is essential for CXCL12 scavenging and interneuron migration, whereas β-arrestin is dispensable, clarifying the minimal signal required for physiological scavenging.","evidence":"Phospho-deficient and β-arrestin-KO knock-in mice with in vivo interneuron migration, CXCL12 levels, and CXCR4 degradation assays","pmids":["30726732"],"confidence":"High","gaps":["Identity of the kinase(s) responsible for in vivo phosphorylation not resolved in this study","Alternative internalization pathways not characterized"]},{"year":2020,"claim":"ACKR3 was established as a broad-spectrum opioid peptide scavenger, extending its ligand repertoire beyond chemokines and peptide hormones and positioning it as a regulator of endogenous opioid tone.","evidence":"Radioligand binding, β-arrestin recruitment, in vitro scavenging assays, ex vivo rat brain pharmacology with ACKR3-selective competitor LIH383","pmids":["32561830"],"confidence":"High","gaps":["In vivo behavioral consequences of ACKR3 opioid scavenging not shown","Whether opioid scavenging involves distinct internalization trafficking from chemokine scavenging unknown"]},{"year":2021,"claim":"Fine-mapping of the ACKR3 C-tail identified T352/S355 as the critical phosphorylation cluster for β-arrestin-1 recruitment, with GRK2/3 as the responsible kinases, and demonstrated that ACKR3 can internalize via β-arrestin-independent pathways.","evidence":"BRET/FRET sensors, phosphosite mutagenesis, GRK co-expression/knockdown in HEK293T cells","pmids":["33799570"],"confidence":"Medium","gaps":["In vivo relevance of individual phosphosites not tested","Identity of β-arrestin-independent internalization pathway not determined"]},{"year":2022,"claim":"Platelet-specific ACKR3 deletion revealed a novel antithrombotic axis: ACKR3 agonism shifts platelet lipid metabolism toward 12-HETrE (from DGLA), which cooperates with prostacyclin receptor/Gαs to activate cAMP/PKA-dependent platelet inhibition, connecting ACKR3 to hemostasis.","evidence":"Megakaryocyte/platelet-specific Ackr3 conditional knockout mice, in vivo thrombosis and ischemia-reperfusion models, targeted lipidomics","pmids":["35383158","34905596"],"confidence":"High","gaps":["How ACKR3 engagement alters lipid enzyme activity is unknown","Whether platelet ACKR3 also scavenges chemokines in the hemostatic context not addressed"]},{"year":2023,"claim":"Comprehensive transducer profiling confirmed ACKR3 is fully uncoupled from all G proteins while engaging β-arrestin predominantly via GRK5/6, and showed that CXCL12-activated ACKR3 and CXCR4 induce distinct β-arrestin conformations, explaining divergent downstream signaling from the same ligand.","evidence":"Full transducer-coupling panel, β-arrestin conformation BRET sensors, GRK isoform-specific assays, phosphosite mutagenesis in HEK293 cells","pmids":["37558722"],"confidence":"High","gaps":["Structural basis of distinct β-arrestin conformations not solved","Downstream effectors of ACKR3-specific β-arrestin conformation unidentified"]},{"year":null,"claim":"Key unresolved questions include the structural basis for ACKR3's multi-ligand promiscuity (chemokines, adrenomedullin, opioids), the identity and regulation of β-arrestin-independent internalization pathways, the mechanism by which ACKR3 reprograms platelet lipid metabolism, and whether ACKR3 opioid scavenging modulates pain or addiction behaviors in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of ACKR3 with a non-chemokine ligand","β-arrestin-independent internalization pathway identity unknown","In vivo behavioral role of opioid scavenging untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,3,4,6,7,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5,17]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,16]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,7,15]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[3,14,15,16]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[2,3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,3,8,16,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,5,10,12]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[17]}],"complexes":["CXCR4/ACKR3 heterodimer"],"partners":["CXCR4","ARRB2","ARRB1","GRK2","GRK3","GRK5","GRK6","EGFR"],"other_free_text":[]},"mechanistic_narrative":"ACKR3 (CXCR7) is an atypical chemokine receptor that functions primarily as a ligand scavenger and biased signaling receptor, regulating the bioavailability of chemokines (CXCL12, CXCL11), adrenomedullin-family peptides, and opioid peptides for their cognate classical receptors [PMID:16107333, PMID:25203207, PMID:32561830]. ACKR3 does not couple to G proteins but signals through β-arrestin recruitment—driven by GRK2/3/5/6-mediated C-tail phosphorylation—to activate ERK1/2 and AKT pathways, and undergoes constitutive dynamin-dependent internalization and recycling that underpins its scavenging function [PMID:37558722, PMID:22300987, PMID:33799570]. It forms constitutive heterodimers with CXCR4, modulating CXCR4-dependent Gαi signaling and calcium responses, and regulates plasma CXCL12 levels through endothelial scavenging to shape leukocyte migration, cortical interneuron positioning, oligodendrocyte maturation, and cardiac valve development [PMID:19380869, PMID:24116850, PMID:30726732, PMID:21246655]. In platelets, ACKR3 agonism shifts lipid metabolism toward antithrombotic mediators (12-HETrE) that engage a cAMP/PKA inhibitory pathway, suppressing platelet activation and thrombosis [PMID:35383158, PMID:34905596]."},"prefetch_data":{"uniprot":{"accession":"P25106","full_name":"Atypical chemokine receptor 3","aliases":["C-X-C chemokine receptor type 7","CXC-R7","CXCR-7","Chemokine orphan receptor 1","G-protein coupled receptor 159","G-protein coupled receptor RDC1 homolog","RDC-1"],"length_aa":362,"mass_kda":41.5,"function":"Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1 (PubMed:16107333, PubMed:19255243, PubMed:19380869, PubMed:20161793, PubMed:22300987). Chemokine binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway (PubMed:16940167, PubMed:18653785, PubMed:20018651). Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness (PubMed:16940167, PubMed:18653785). In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival (PubMed:16940167, PubMed:20388803). Not involved in cell migration, adhesion or proliferation of normal hematopoietic progenitors but activated by CXCL11 in malignant hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1) and enhanced cell adhesion and migration (PubMed:17804806, PubMed:18653785, PubMed:19641136, PubMed:20887389). Plays a regulatory role in CXCR4-mediated activation of cell surface integrins by CXCL12 (PubMed:18653785). Required for heart valve development (PubMed:17804806). Regulates axon guidance in the oculomotor system through the regulation of CXCL12 levels (PubMed:31211835). Acts as a receptor for SHLP2, mediating its effects on activation of proopiomelanocortin neurons in the arcuate nucleus of the hypothalamus which leads to suppression of food intake and increased energy expenditure (PubMed:37468558) (Microbial infection) Acts as a coreceptor with CXCR4 for a restricted number of HIV isolates","subcellular_location":"Cell membrane; Early endosome; Recycling endosome","url":"https://www.uniprot.org/uniprotkb/P25106/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACKR3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACKR3","total_profiled":1310},"omim":[{"mim_id":"621003","title":"TRANSCRIPTION FACTOR Sp9; SP9","url":"https://www.omim.org/entry/621003"},{"mim_id":"619215","title":"OCULOMOTOR-ABDUCENS SYNKINESIS; OCABSN","url":"https://www.omim.org/entry/619215"},{"mim_id":"610376","title":"ATYPICAL CHEMOKINE RECEPTOR 3; ACKR3","url":"https://www.omim.org/entry/610376"},{"mim_id":"151610","title":"OCULOMOTOR-LEVATOR SYNKINESIS; OCLEVS","url":"https://www.omim.org/entry/151610"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ACKR3"},"hgnc":{"alias_symbol":["RDC1","GPR159"],"prev_symbol":["CMKOR1","CXCR7"]},"alphafold":{"accession":"P25106","domains":[{"cath_id":"1.20.1070.10","chopping":"14-244_254-319","consensus_level":"medium","plddt":86.1262,"start":14,"end":319}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25106","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25106-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25106-F1-predicted_aligned_error_v6.png","plddt_mean":82.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACKR3","jax_strain_url":"https://www.jax.org/strain/search?query=ACKR3"},"sequence":{"accession":"P25106","fasta_url":"https://rest.uniprot.org/uniprotkb/P25106.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25106/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25106"}},"corpus_meta":[{"pmid":"16107333","id":"PMC_16107333","title":"The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16107333","citation_count":854,"is_preprint":false},{"pmid":"20839032","id":"PMC_20839032","title":"CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.","date":"2010","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20839032","citation_count":606,"is_preprint":false},{"pmid":"19380869","id":"PMC_19380869","title":"CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19380869","citation_count":506,"is_preprint":false},{"pmid":"18057003","id":"PMC_18057003","title":"The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18057003","citation_count":387,"is_preprint":false},{"pmid":"21349998","id":"PMC_21349998","title":"CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21349998","citation_count":342,"is_preprint":false},{"pmid":"33363463","id":"PMC_33363463","title":"The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33363463","citation_count":240,"is_preprint":false},{"pmid":"20869949","id":"PMC_20869949","title":"Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20869949","citation_count":206,"is_preprint":false},{"pmid":"31874281","id":"PMC_31874281","title":"The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.","date":"2019","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/31874281","citation_count":194,"is_preprint":false},{"pmid":"23153575","id":"PMC_23153575","title":"CXCR7 impact on CXCL12 biology and disease.","date":"2012","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23153575","citation_count":174,"is_preprint":false},{"pmid":"37497001","id":"PMC_37497001","title":"CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37497001","citation_count":159,"is_preprint":false},{"pmid":"20380740","id":"PMC_20380740","title":"Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells.","date":"2010","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/20380740","citation_count":149,"is_preprint":false},{"pmid":"31507535","id":"PMC_31507535","title":"The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31507535","citation_count":131,"is_preprint":false},{"pmid":"29123467","id":"PMC_29123467","title":"The Role of SDF-1/CXCR4/CXCR7 in Neuronal Regeneration after Cerebral Ischemia.","date":"2017","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29123467","citation_count":106,"is_preprint":false},{"pmid":"19835865","id":"PMC_19835865","title":"The role of stromal-derived factor-1--CXCR7 axis in development and cancer.","date":"2009","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19835865","citation_count":104,"is_preprint":false},{"pmid":"30952632","id":"PMC_30952632","title":"Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30952632","citation_count":101,"is_preprint":false},{"pmid":"24742460","id":"PMC_24742460","title":"Lhx6 directly regulates Arx and CXCR7 to determine cortical interneuron fate and laminar position.","date":"2014","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/24742460","citation_count":100,"is_preprint":false},{"pmid":"26212008","id":"PMC_26212008","title":"CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26212008","citation_count":98,"is_preprint":false},{"pmid":"32561830","id":"PMC_32561830","title":"The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32561830","citation_count":97,"is_preprint":false},{"pmid":"23382785","id":"PMC_23382785","title":"Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease.","date":"2013","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/23382785","citation_count":96,"is_preprint":false},{"pmid":"23279723","id":"PMC_23279723","title":"An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology.","date":"2012","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/23279723","citation_count":87,"is_preprint":false},{"pmid":"22457824","id":"PMC_22457824","title":"Ubiquitination of CXCR7 controls receptor trafficking.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22457824","citation_count":87,"is_preprint":false},{"pmid":"25203207","id":"PMC_25203207","title":"Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development.","date":"2014","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/25203207","citation_count":82,"is_preprint":false},{"pmid":"33937018","id":"PMC_33937018","title":"CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33937018","citation_count":79,"is_preprint":false},{"pmid":"24116850","id":"PMC_24116850","title":"Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels.","date":"2014","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24116850","citation_count":77,"is_preprint":false},{"pmid":"25168820","id":"PMC_25168820","title":"The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25168820","citation_count":77,"is_preprint":false},{"pmid":"19625779","id":"PMC_19625779","title":"CXCL12, CXCR4 and CXCR7 expression in brain metastases.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19625779","citation_count":72,"is_preprint":false},{"pmid":"24991762","id":"PMC_24991762","title":"CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24991762","citation_count":71,"is_preprint":false},{"pmid":"21246655","id":"PMC_21246655","title":"The chemokine receptor CXCR7 functions to regulate cardiac valve remodeling.","date":"2011","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/21246655","citation_count":69,"is_preprint":false},{"pmid":"21154415","id":"PMC_21154415","title":"Activation of CXCR7 receptor promotes oligodendroglial cell maturation.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21154415","citation_count":67,"is_preprint":false},{"pmid":"20889540","id":"PMC_20889540","title":"CXCR7 protein is not expressed on human or mouse leukocytes.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20889540","citation_count":67,"is_preprint":false},{"pmid":"24629239","id":"PMC_24629239","title":"Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24629239","citation_count":67,"is_preprint":false},{"pmid":"30726732","id":"PMC_30726732","title":"ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30726732","citation_count":65,"is_preprint":false},{"pmid":"32758634","id":"PMC_32758634","title":"Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32758634","citation_count":65,"is_preprint":false},{"pmid":"32956018","id":"PMC_32956018","title":"The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.","date":"2020","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/32956018","citation_count":65,"is_preprint":false},{"pmid":"28670693","id":"PMC_28670693","title":"CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.","date":"2017","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/28670693","citation_count":65,"is_preprint":false},{"pmid":"29022185","id":"PMC_29022185","title":"Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.","date":"2017","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29022185","citation_count":64,"is_preprint":false},{"pmid":"26100110","id":"PMC_26100110","title":"CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26100110","citation_count":64,"is_preprint":false},{"pmid":"26578388","id":"PMC_26578388","title":"Crosstalk between SDF-1/CXCR4 and SDF-1/CXCR7 in cardiac stem cell migration.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26578388","citation_count":59,"is_preprint":false},{"pmid":"31662319","id":"PMC_31662319","title":"FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice.","date":"2019","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31662319","citation_count":56,"is_preprint":false},{"pmid":"24733828","id":"PMC_24733828","title":"Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system.","date":"2014","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24733828","citation_count":56,"is_preprint":false},{"pmid":"29398278","id":"PMC_29398278","title":"Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29398278","citation_count":55,"is_preprint":false},{"pmid":"19821487","id":"PMC_19821487","title":"CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1.","date":"2010","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19821487","citation_count":55,"is_preprint":false},{"pmid":"22531719","id":"PMC_22531719","title":"CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients.","date":"2012","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22531719","citation_count":55,"is_preprint":false},{"pmid":"31273063","id":"PMC_31273063","title":"CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31273063","citation_count":53,"is_preprint":false},{"pmid":"19594447","id":"PMC_19594447","title":"Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.","date":"2009","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/19594447","citation_count":52,"is_preprint":false},{"pmid":"29903572","id":"PMC_29903572","title":"Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29903572","citation_count":51,"is_preprint":false},{"pmid":"9510554","id":"PMC_9510554","title":"Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1.","date":"1998","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9510554","citation_count":51,"is_preprint":false},{"pmid":"29606504","id":"PMC_29606504","title":"A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29606504","citation_count":51,"is_preprint":false},{"pmid":"31548340","id":"PMC_31548340","title":"Modulators of CXCR4 and CXCR7/ACKR3 Function.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31548340","citation_count":50,"is_preprint":false},{"pmid":"27082011","id":"PMC_27082011","title":"Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27082011","citation_count":48,"is_preprint":false},{"pmid":"34494495","id":"PMC_34494495","title":"Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate.","date":"2021","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34494495","citation_count":46,"is_preprint":false},{"pmid":"28820530","id":"PMC_28820530","title":"CXCR7 attenuates the TGF-β-induced endothelial-to-mesenchymal transition and pulmonary fibrosis.","date":"2017","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/28820530","citation_count":46,"is_preprint":false},{"pmid":"23865743","id":"PMC_23865743","title":"CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1α.","date":"2013","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23865743","citation_count":44,"is_preprint":false},{"pmid":"30745320","id":"PMC_30745320","title":"The Role of ACKR3 in Breast, Lung, and Brain Cancer.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30745320","citation_count":42,"is_preprint":false},{"pmid":"21084856","id":"PMC_21084856","title":"Expression of the new CXCL12 receptor, CXCR7, in gliomas.","date":"2011","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21084856","citation_count":42,"is_preprint":false},{"pmid":"18956235","id":"PMC_18956235","title":"Differential expression of RDC1/CXCR7 in the human placenta.","date":"2008","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18956235","citation_count":41,"is_preprint":false},{"pmid":"35383158","id":"PMC_35383158","title":"ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35383158","citation_count":41,"is_preprint":false},{"pmid":"30224544","id":"PMC_30224544","title":"Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/30224544","citation_count":41,"is_preprint":false},{"pmid":"24853339","id":"PMC_24853339","title":"The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24853339","citation_count":40,"is_preprint":false},{"pmid":"26216880","id":"PMC_26216880","title":"Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26216880","citation_count":40,"is_preprint":false},{"pmid":"31481460","id":"PMC_31481460","title":"Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31481460","citation_count":39,"is_preprint":false},{"pmid":"26369824","id":"PMC_26369824","title":"Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.","date":"2016","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26369824","citation_count":39,"is_preprint":false},{"pmid":"24277075","id":"PMC_24277075","title":"CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24277075","citation_count":39,"is_preprint":false},{"pmid":"29980568","id":"PMC_29980568","title":"Binding of Dickkopf-3 to CXCR7 Enhances Vascular Progenitor Cell Migration and Degradable Graft Regeneration.","date":"2018","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/29980568","citation_count":39,"is_preprint":false},{"pmid":"35406582","id":"PMC_35406582","title":"Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35406582","citation_count":37,"is_preprint":false},{"pmid":"12118328","id":"PMC_12118328","title":"Fusion of RDC1 with HMGA2 in lipomas as the result of chromosome aberrations involving 2q35-37 and 12q13-15.","date":"2002","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12118328","citation_count":37,"is_preprint":false},{"pmid":"26551719","id":"PMC_26551719","title":"Role of chemokine receptors CXCR4 and CXCR7 for platelet function.","date":"2015","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/26551719","citation_count":37,"is_preprint":false},{"pmid":"27029529","id":"PMC_27029529","title":"Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/27029529","citation_count":37,"is_preprint":false},{"pmid":"22300987","id":"PMC_22300987","title":"Carboxy-terminus of CXCR7 regulates receptor localization and function.","date":"2012","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22300987","citation_count":36,"is_preprint":false},{"pmid":"21294125","id":"PMC_21294125","title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21294125","citation_count":36,"is_preprint":false},{"pmid":"23289420","id":"PMC_23289420","title":"CXCR4 and CXCR7 form a functional receptor unit for SDF-1/CXCL12 in primary rodent microglia.","date":"2013","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/23289420","citation_count":36,"is_preprint":false},{"pmid":"34905596","id":"PMC_34905596","title":"Platelet ACKR3/CXCR7 favors antiplatelet lipids over an atherothrombotic lipidome and regulates thromboinflammation.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34905596","citation_count":35,"is_preprint":false},{"pmid":"27238288","id":"PMC_27238288","title":"Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.","date":"2016","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27238288","citation_count":35,"is_preprint":false},{"pmid":"26921391","id":"PMC_26921391","title":"β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/26921391","citation_count":34,"is_preprint":false},{"pmid":"32098047","id":"PMC_32098047","title":"Advances in CXCR7 Modulators.","date":"2020","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32098047","citation_count":33,"is_preprint":false},{"pmid":"27598329","id":"PMC_27598329","title":"Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.","date":"2016","source":"Expert opinion on drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27598329","citation_count":33,"is_preprint":false},{"pmid":"25079359","id":"PMC_25079359","title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25079359","citation_count":33,"is_preprint":false},{"pmid":"35674847","id":"PMC_35674847","title":"Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium.","date":"2022","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35674847","citation_count":32,"is_preprint":false},{"pmid":"33799570","id":"PMC_33799570","title":"Differential Involvement of ACKR3 C-Tail in β-Arrestin Recruitment, Trafficking and Internalization.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33799570","citation_count":32,"is_preprint":false},{"pmid":"35846294","id":"PMC_35846294","title":"Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35846294","citation_count":30,"is_preprint":false},{"pmid":"29257351","id":"PMC_29257351","title":"CXCR7 regulates breast tumor metastasis and angiogenesis in vivo and in vitro.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29257351","citation_count":29,"is_preprint":false},{"pmid":"26912435","id":"PMC_26912435","title":"Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.","date":"2016","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26912435","citation_count":28,"is_preprint":false},{"pmid":"33860204","id":"PMC_33860204","title":"Proadrenomedullin N-Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7.","date":"2021","source":"ACS pharmacology & translational science","url":"https://pubmed.ncbi.nlm.nih.gov/33860204","citation_count":28,"is_preprint":false},{"pmid":"26934559","id":"PMC_26934559","title":"CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26934559","citation_count":27,"is_preprint":false},{"pmid":"29146732","id":"PMC_29146732","title":"miR-539-5p inhibits experimental choroidal neovascularization by targeting CXCR7.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29146732","citation_count":27,"is_preprint":false},{"pmid":"30804329","id":"PMC_30804329","title":"CXCR7 promotes melanoma tumorigenesis via Src kinase signaling.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30804329","citation_count":26,"is_preprint":false},{"pmid":"24582769","id":"PMC_24582769","title":"Atorvastatin inhibits CXCR7 induction to reduce macrophage migration.","date":"2014","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24582769","citation_count":26,"is_preprint":false},{"pmid":"37558722","id":"PMC_37558722","title":"Molecular insights into intrinsic transducer-coupling bias in the CXCR4-CXCR7 system.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37558722","citation_count":25,"is_preprint":false},{"pmid":"32883765","id":"PMC_32883765","title":"Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.","date":"2020","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32883765","citation_count":24,"is_preprint":false},{"pmid":"37950281","id":"PMC_37950281","title":"Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37950281","citation_count":23,"is_preprint":false},{"pmid":"29433559","id":"PMC_29433559","title":"CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells.","date":"2018","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29433559","citation_count":23,"is_preprint":false},{"pmid":"24814201","id":"PMC_24814201","title":"The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma.","date":"2014","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/24814201","citation_count":23,"is_preprint":false},{"pmid":"38920657","id":"PMC_38920657","title":"Crosstalk between CXCL12/CXCR4/ACKR3 and the STAT3 Pathway.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38920657","citation_count":22,"is_preprint":false},{"pmid":"33129326","id":"PMC_33129326","title":"Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells.","date":"2020","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/33129326","citation_count":22,"is_preprint":false},{"pmid":"27460092","id":"PMC_27460092","title":"Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27460092","citation_count":22,"is_preprint":false},{"pmid":"29250768","id":"PMC_29250768","title":"Critical involvement of atypical chemokine receptor CXCR7 in allergic airway inflammation.","date":"2018","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29250768","citation_count":22,"is_preprint":false},{"pmid":"32210974","id":"PMC_32210974","title":"Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32210974","citation_count":21,"is_preprint":false},{"pmid":"25084358","id":"PMC_25084358","title":"Chemokine receptor CXCR7 is a functional receptor for CXCL12 in brain endothelial cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25084358","citation_count":21,"is_preprint":false},{"pmid":"29601107","id":"PMC_29601107","title":"Characterization of a chimeric chemokine as a specific ligand for ACKR3.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/29601107","citation_count":21,"is_preprint":false},{"pmid":"31904910","id":"PMC_31904910","title":"CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31904910","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52945,"output_tokens":7484,"usd":0.135547},"stage2":{"model":"claude-opus-4-6","input_tokens":11384,"output_tokens":3907,"usd":0.231893},"total_usd":0.36744,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL12/SDF-1 binds to and signals through RDC1 (renamed CXCR7/ACKR3) with high affinity (apparent KD ~0.4 nM), promoting receptor internalization and chemotactic signals in CXCR4-negative cells expressing RDC1, establishing RDC1 as a bona fide CXCL12 receptor in T lymphocytes.\",\n      \"method\": \"Radioligand binding assay, chemotaxis assay with anti-RDC1 antibody blockade, receptor internalization assay in CXCR4-negative cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (binding kinetics, functional chemotaxis, internalization) in a single foundational paper; widely replicated\",\n      \"pmids\": [\"16107333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCR7 forms constitutive heterodimers with CXCR4 (as efficiently as homodimers), does not itself trigger Gαi-protein-dependent signaling despite constitutive interaction with Gαi proteins, and impairs CXCR4-promoted Gαi-protein activation and calcium responses when co-expressed, identifying CXCR4/CXCR7 heterodimers as distinct functional units that modulate CXCL12 signaling.\",\n      \"method\": \"BRET/FRET energy transfer assays for protein–protein interactions, G protein signaling assays, calcium flux assays, primary T cell co-expression studies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal BRET/FRET assays plus functional G-protein and calcium readouts; moderate replication\",\n      \"pmids\": [\"19380869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCR7 is constitutively ubiquitinated, and this ubiquitination is required for correct trafficking from and to the plasma membrane; CXCL12 treatment causes reversible de-ubiquitination. Internalization depends on both β-arrestin and Ser/Thr residues at the C-terminus, and C-terminal Lys residues are essential for surface delivery.\",\n      \"method\": \"Mutagenesis of C-terminal Ser/Thr and Lys residues, ubiquitination assays, internalization/recycling assays, β-arrestin depletion\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct mutagenesis plus functional trafficking assays with multiple controls in a single study\",\n      \"pmids\": [\"22457824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The C-terminal intracellular tail of CXCR7 controls receptor localization (wild-type receptor localizes predominantly to intracellular vesicles), constitutive internalization, ligand-dependent β-arrestin-2 recruitment, chemokine scavenging, and CXCL12-stimulated ERK1/2 activation; dynamin-dependent internalization facilitates β-arrestin-2 association and ERK1/2 signaling.\",\n      \"method\": \"Carboxy-terminus deletion mutants, firefly luciferase complementation for β-arrestin-2 recruitment, dynamin inhibition, ERK1/2 phosphorylation assays, CXCL12 scavenging assays\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution with multiple deletion mutants, orthogonal assays for trafficking, signaling, and scavenging\",\n      \"pmids\": [\"22300987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCR7 acts as a decoy/scavenger receptor for adrenomedullin (AM), controlling AM bioavailability and downstream GPCR-mediated cardiac and lymphatic vascular development; Cxcr7−/− mice show gain-of-function cardiac and lymphatic phenotypes rescued by genetic depletion of the adrenomedullin ligand.\",\n      \"method\": \"Genetic mouse knockout (Cxcr7−/−), adrenomedullin ligand double-knockout rescue epistasis, cardiac/lymphatic phenotyping\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous genetic epistasis with double-mutant rescue establishing ligand–receptor relationship in vivo\",\n      \"pmids\": [\"25203207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ACKR3 phosphorylation (but not β-arrestin) is essential for its function as a CXCL12 scavenger controlling interneuron migration; phosphorylation-deficient ACKR3 mice exhibit major interneuron migration defects accompanied by excess CXCL12, lysosomal CXCR4 degradation, and loss of CXCR4 responsiveness, demonstrating that ACKR3 sequesters CXCL12 to prevent over-activation and subsequent loss of CXCR4.\",\n      \"method\": \"Phosphorylation-deficient and β-arrestin-deficient knock-in mice, in vivo interneuron migration assays, CXCL12 level measurements, CXCR4 degradation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic models (phospho-deficient and β-arrestin KO) with defined cellular phenotype; mechanistic dissection of phosphorylation vs. β-arrestin roles\",\n      \"pmids\": [\"30726732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ACKR3/CXCR7 is a broad-spectrum scavenger receptor for opioid peptides (especially enkephalins and dynorphins), functioning as a negative regulator of opioid peptide availability for classical opioid receptors; an ACKR3-selective competitor peptide (LIH383) potentiates opioid peptide activity toward classical receptors in rat brain.\",\n      \"method\": \"Radioligand binding, β-arrestin recruitment assays, in vitro scavenging assays, rat brain ex vivo pharmacology with LIH383 competitor peptide\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal in vitro assays plus in vivo pharmacological validation with selective tool compound\",\n      \"pmids\": [\"32561830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endothelial CXCR7 regulates circulating CXCL12 levels; genetic deletion or pharmacological inhibition of CXCR7 causes pronounced increases in plasma CXCL12 and impairs leukocyte migration toward local CXCL12 sources; CXCR7 protein is expressed primarily on venule endothelium and arteriole smooth muscle cells in humans and mice.\",\n      \"method\": \"CXCR7 genetic knockout mice, pharmacological inhibition, ELISA for plasma CXCL12, competitive binding assay, flow cytometry, immunohistochemistry with CXCR7+/lacZ reporter mice\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complementary genetic and pharmacological approaches with quantitative plasma CXCL12 measurement and reporter mouse localization\",\n      \"pmids\": [\"24116850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCR7 activates MAPK/ERK signaling through β-arrestin 2-dependent, ligand-independent mechanisms in prostate cancer, driving enzalutamide resistance; AR directly represses CXCR7 by binding an enhancer 110 kb downstream of the gene.\",\n      \"method\": \"Transcriptome analysis, ChIP assay for AR binding, β-arrestin 2 depletion, ERK phosphorylation assays, in vitro and in vivo CRPC growth assays, patient specimen analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP for AR direct binding, β-arrestin-dependent ERK signaling demonstrated by depletion, in vitro/in vivo confirmation\",\n      \"pmids\": [\"30952632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCR7 increases cell-associated CXCL12 to a significantly greater extent than CXCR4, consistent with a scavenging/internalization function; CXCL12 fused to Gaussia luciferase activates CXCR4-dependent signaling comparably to unfused CXCL12.\",\n      \"method\": \"Bioluminescent CXCL12-Gaussia luciferase fusion protein binding assay, multiwell plate chemokine uptake quantification, CXCR4 signaling assays\",\n      \"journal\": \"BioTechniques\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct quantitative assay but single lab, single paper\",\n      \"pmids\": [\"19594447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCR7 is required for semilunar cardiac valve development; Cxcr7 germline deletion causes aortic and pulmonary valve stenosis with increased mesenchymal cell proliferation and elevated phospho-Smad1/5/8 (BMP signaling); Tie2-Cre conditional knockout recapitulates the phenotype, implicating endocardial cell CXCR7 function.\",\n      \"method\": \"Germline and Tie2-Cre conditional knockout mice, histological phenotyping, phospho-Smad1/5/8 immunostaining\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic loss-of-function with conditional rescue identifying cell-type specificity; BMP pathway link is correlative\",\n      \"pmids\": [\"21246655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CXCR7 participates in CXCL12-induced cycling and survival of human CD34+ hematopoietic stem/progenitor cells via β-arrestin 2-dependent Akt activation; β-arrestin 2 translocates to the nucleus after CXCL12 treatment in a manner requiring both CXCR7 and CXCR4, and β-arrestin silencing reduces Akt activation.\",\n      \"method\": \"CXCR7 blocking antibody, β-arrestin 2 colocalization/nuclear translocation imaging, siRNA silencing of β-arrestins, Akt phosphorylation assays, colony formation and cell cycle assays in primary human CD34+ cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in primary human cells; single lab\",\n      \"pmids\": [\"24277075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Lhx6 transcription factor directly binds an intronic CXCR7 enhancer in vivo, and CXCR7 regulates laminar positioning of MGE-derived cortical interneurons in neonatal cortex, as shown by MGE complementation/transplantation rescue assays.\",\n      \"method\": \"ChIP for Lhx6 binding at CXCR7 enhancer, in vivo MGE complementation/transplantation assay, interneuron lamination phenotyping in Lhx6−/− mice\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP binding plus in vivo transplantation rescue; single paper\",\n      \"pmids\": [\"24742460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Dickkopf-3 (Dkk3) physically binds CXCR7 with high affinity (Kd ~14 nmol/L) and triggers ERK1/2, PI3K/AKT, Rac1, and RhoA signaling to drive vascular progenitor cell migration; CXCR7 blocking antibodies impair stem/progenitor cell recruitment into tissue-engineered vessel grafts.\",\n      \"method\": \"Co-immunoprecipitation, saturation binding assay, overexpression/knockdown functional migration assays, in vivo tissue-engineered vessel graft model with CXCR7 antibody blockade\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — co-IP plus saturation binding establishes interaction; signaling and in vivo functional follow-up; single lab\",\n      \"pmids\": [\"29980568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HHV-8-encoded vCCL2/vMIP-II is a high-affinity ligand for ACKR3, acting as a partial agonist that induces β-arrestin recruitment, reduces surface ACKR3 levels, delivers receptor to endosomes, and reduces vCCL2-triggered MAP kinase and PI3K/Akt signaling through other chemokine receptors.\",\n      \"method\": \"β-arrestin recruitment assay, receptor surface level measurement by flow cytometry, endosomal trafficking imaging, MAP kinase and PI3K/Akt signaling assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays; single lab demonstrating novel ligand–receptor interaction\",\n      \"pmids\": [\"27238288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A single cluster of phosphorylated residues on the ACKR3 C-tail (particularly T352 and S355) determines β-arrestin1 recruitment; GRK2 and GRK3 phosphorylate ACKR3 and are key for β-arrestin recruitment and receptor internalization; ACKR3 can internalize independently of β-arrestins via alternative pathways; upon activation ACKR3 internalizes and recycles to the cell membrane.\",\n      \"method\": \"BRET/FRET-based sensors in HEK293T cells, phosphorylation site mutagenesis, GRK co-expression/knockdown, receptor internalization and trafficking assays\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with BRET/FRET sensors; single lab but comprehensive mechanistic dissection\",\n      \"pmids\": [\"33799570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCR7 lacks G-protein coupling while maintaining robust β-arrestin recruitment (predominantly via GRK5/6); CXCR7 and CXCR4 induce distinct β-arrestin conformations when activated by the same agonist CXCL12; CXCR7, unlike CXCR4, fails to activate ERK1/2 MAP kinase; a single phosphorylation site on CXCR7 is key for β-arrestin recruitment and endosomal localization.\",\n      \"method\": \"Comprehensive transducer-coupling characterization, βarr conformation BRET sensors, GRK isoform-specific assays, phosphorylation site mutagenesis, ERK1/2 assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — comprehensive reconstitution with multiple sensors and mutagenesis; rigorous mechanistic dissection of biased signaling\",\n      \"pmids\": [\"37558722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Megakaryocyte/platelet-specific deletion of ACKR3 enhances platelet activation and thrombosis in vitro and in vivo; ACKR3 ligation with specific agonists inhibits platelet activation, thrombus formation, and attenuates tissue injury in ischemic myocardium and brain; ACKR3 agonism favors antithrombotic lipids (DGLA, 12-HETrE) over prothrombotic lipids, and 12-HETrE coordinates with Gαs-coupled prostacyclin receptor to trigger cAMP/PKA-mediated platelet inhibition.\",\n      \"method\": \"Platelet-specific Ackr3 conditional knockout mice, in vitro platelet activation assays, in vivo thrombosis and ischemia-reperfusion models, targeted and untargeted lipidomics (micro-UHPLC-ESI-MS/MS)\",\n      \"journal\": \"Nature communications / Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-specific genetic KO with defined phenotype plus mechanistic lipidomics and pharmacological agonist validation in vivo\",\n      \"pmids\": [\"35383158\", \"34905596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Arterial endothelial ACKR3 promotes atherosclerosis by mediating immune cell adhesion to vascular endothelium through MAPK (ERK1/2) and NF-κB p65 pathways; smooth muscle cell or hematopoietic ACKR3 deficiency does not impact atherosclerosis.\",\n      \"method\": \"Apoe−/− mice with endothelial- or smooth muscle cell-specific Ackr3 deletion, atherosclerosis quantification, adhesion molecule expression, ERK1/2 and NF-κB p65 phosphorylation assays, ACKR3 silencing in human coronary artery endothelial cells\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic deletion with pathway mechanistic follow-up; single lab\",\n      \"pmids\": [\"35674847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PAMP-12 (proadrenomedullin N-terminal 20 peptide processed form) is a high-potency agonist for ACKR3, inducing β-arrestin recruitment and efficient receptor internalization without activating G protein or ERK signaling, identifying ACKR3 as a regulator of PAMP-12 availability for its primary receptor MrgX2.\",\n      \"method\": \"β-arrestin recruitment assay, G protein signaling assay, ERK assay, receptor internalization assay, comparison with ADM and CGRP family members with/without RAMPs\",\n      \"journal\": \"ACS pharmacology & translational science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays; single lab; novel ligand identification\",\n      \"pmids\": [\"33860204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCR7 activates MAPK-ERK signaling via β-arrestin (not G-protein) to drive acquired resistance to EGFR TKIs in NSCLC; depletion of CXCR7 inhibits the MAPK pathway, attenuates EGFR TKI resistance, and induces mesenchymal-to-epithelial transition.\",\n      \"method\": \"CXCR7 depletion by siRNA/shRNA, ERK phosphorylation assays, EGFR TKI resistance models in vitro, patient specimen CXCR7 expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional depletion with defined signaling readout; single lab; mechanistic β-arrestin link inferred\",\n      \"pmids\": [\"31273063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"MIF (macrophage migration inhibitory factor) is identified as a ligand for CXCR7, activating AKT signaling and inducing cell-cycle gene expression; AR directly represses CXCR7 expression (shown by CRISPR/Cas9 editing); the MIF/CXCR7/AKT pathway drives CRPC growth independent of CXCL12/CXCR4.\",\n      \"method\": \"CRISPR/Cas9-mediated AR binding site deletion, ligand binding assay for MIF-CXCR7, AKT phosphorylation assays, gene expression profiling, in vivo xenograft studies\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR validation of AR binding plus functional ligand identification; single lab\",\n      \"pmids\": [\"30224544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCR7 transactivates EGFR in a β-arrestin-2-independent (G-protein-independent) manner; β-arrestin-2 acts as a negative regulator (tumor suppressor) of CXCR7/Src/EGFR-mediated mitogenic signaling; β-arrestin-2 depletion increases Src phosphorylation, EGFR Tyr-1110 phosphorylation, ERK1/2 activation, and nuclear EGFR translocation.\",\n      \"method\": \"β-arrestin-2 shRNA knockdown, cDNA knock-in, proximity ligation assay for CXCR7-EGFR colocalization, phosphorylation assays (Src, EGFR, ERK1/2, Akt), nuclear EGFR translocation imaging\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple signaling assays with knockdown; single lab; mechanistic β-arrestin-2 role defined\",\n      \"pmids\": [\"26921391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCR7 interacts with EGFR in breast cancer cells, and β-arrestin-2 acts as a scaffold to enhance CXCR7-dependent activation of EGFR after EGF stimulation; CXCR7 depletion reduces EGFR phosphorylation at Tyr1110 and ERK1/2 phosphorylation.\",\n      \"method\": \"In situ proximity ligation assay (PLA) for CXCR7-EGFR colocalization in cancer tissues/cells, siRNA knockdown of CXCR7 and β-arrestin2, Western blotting for phospho-EGFR and phospho-ERK1/2\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — PLA establishes proximity plus functional signaling readout; single lab\",\n      \"pmids\": [\"25168820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCR7 promotes melanoma proliferation via β-arrestin2-dependent Src kinase phosphorylation; CXCR7-Src axis stimulates eIF4E phosphorylation, accelerating HIF-1α translation and VEGF secretion to drive angiogenesis.\",\n      \"method\": \"CXCR7 knockout, Src kinase inhibitor PP1, β-arrestin2 siRNA, eIF4E and HIF-1α western blotting, VEGF ELISA, in vivo xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — genetic knockout plus pharmacological inhibition with defined pathway; single lab\",\n      \"pmids\": [\"30804329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCR7 promotes oligodendroglial precursor cell maturation and myelin expression via CXCL12 stimulation; pharmacological inhibition of CXCR7 blocks CXCL12-dependent oligodendrocyte maturation, while CXCR7 antagonism in vivo augments OPC proliferation and increases mature oligodendrocyte numbers in demyelinated lesions, requiring CXCR4 co-activation.\",\n      \"method\": \"Pharmacological CXCR7 inhibition in primary OPC cultures, CXCR7 antagonist in cuprizone demyelination model in vivo, phospho-S339-CXCR4 antibody, CXCR4 antagonist epistasis\",\n      \"journal\": \"The Journal of experimental medicine / Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo pharmacological inhibition with CXCR4 epistasis; two independent papers\",\n      \"pmids\": [\"24733828\", \"21154415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCR7 activates the Hippo/YAP axis via Gαq/11 and Rho GTPase signaling, causing YAP dephosphorylation and nuclear accumulation in gastric cancer; YAP in turn binds the CXCR7 promoter to transcriptionally upregulate CXCR7, forming a positive feedback loop.\",\n      \"method\": \"ChIP assay for YAP binding at CXCR7 promoter, Gαq/11 and Rho GTPase inhibition, YAP phosphorylation/localization assays, pharmacological CXCR7 inhibition (ACT-1004-1239), in vivo xenograft model\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP for YAP binding plus mechanistic pathway dissection; single lab\",\n      \"pmids\": [\"37950281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TGF-β1 upregulates CXCR7 expression via Smad2/3-dependent signaling in endothelial cells; overexpressed CXCR7 attenuates TGF-β1-induced endothelial-to-mesenchymal transition by inhibiting the Jag1-Notch pathway.\",\n      \"method\": \"Smad2/3 inhibition, CXCR7 overexpression and knockdown in endothelial cells, EndMT marker assays, Jag1-Notch pathway analysis, in vivo mouse lung fibrosis model\",\n      \"journal\": \"Molecular bioSystems\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Smad2/3-dependent transcriptional mechanism plus functional EndMT assays; single lab\",\n      \"pmids\": [\"28820530\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACKR3/CXCR7 is an atypical chemokine receptor that binds CXCL12, CXCL11, adrenomedullin-related peptides, opioid peptides, and viral chemokines with high affinity but does not couple to G proteins; instead it signals constitutively and upon ligand activation through β-arrestin recruitment (facilitated by GRK2/3/5/6-mediated C-tail phosphorylation) and dynamin-dependent internalization to scavenge extracellular chemokines, modulate plasma CXCL12 levels, regulate CXCR4 activity through direct heterodimerization, activate ERK via β-arrestin scaffolding, control cardiac valve and lymphatic development, guide cortical interneuron migration, and inhibit platelet activation through a lipid-mediated cAMP/PKA pathway.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ACKR3 (CXCR7) is an atypical chemokine receptor that functions primarily as a ligand scavenger and biased signaling receptor, regulating the bioavailability of chemokines (CXCL12, CXCL11), adrenomedullin-family peptides, and opioid peptides for their cognate classical receptors [PMID:16107333, PMID:25203207, PMID:32561830]. ACKR3 does not couple to G proteins but signals through β-arrestin recruitment—driven by GRK2/3/5/6-mediated C-tail phosphorylation—to activate ERK1/2 and AKT pathways, and undergoes constitutive dynamin-dependent internalization and recycling that underpins its scavenging function [PMID:37558722, PMID:22300987, PMID:33799570]. It forms constitutive heterodimers with CXCR4, modulating CXCR4-dependent Gαi signaling and calcium responses, and regulates plasma CXCL12 levels through endothelial scavenging to shape leukocyte migration, cortical interneuron positioning, oligodendrocyte maturation, and cardiac valve development [PMID:19380869, PMID:24116850, PMID:30726732, PMID:21246655]. In platelets, ACKR3 agonism shifts lipid metabolism toward antithrombotic mediators (12-HETrE) that engage a cAMP/PKA inhibitory pathway, suppressing platelet activation and thrombosis [PMID:35383158, PMID:34905596].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"The orphan receptor RDC1 was identified as a second high-affinity CXCL12 receptor (renamed CXCR7), resolving whether CXCR4 was the sole receptor for this chemokine and opening the question of how two receptors partition CXCL12 signaling.\",\n      \"evidence\": \"Radioligand binding, chemotaxis, and internalization assays in CXCR4-negative T cells\",\n      \"pmids\": [\"16107333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXCR7 signals through canonical G-protein pathways was untested\", \"Physiological role in vivo unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"CXCR7 was shown to heterodimerize constitutively with CXCR4 and to attenuate CXCR4-Gαi coupling and calcium signaling, establishing that CXCR7 modulates CXCL12 responses indirectly through receptor–receptor interactions rather than canonical G-protein signaling.\",\n      \"evidence\": \"BRET/FRET dimerization assays, G-protein activation and calcium flux assays in co-expressing cells and primary T cells\",\n      \"pmids\": [\"19380869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway downstream of CXCR7 itself unresolved\", \"Scavenging capacity versus CXCR4 not directly compared\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Quantitative comparison showed CXCR7 accumulates more cell-associated CXCL12 than CXCR4, supporting a predominant scavenger function.\",\n      \"evidence\": \"Bioluminescent CXCL12-Gaussia luciferase uptake assay\",\n      \"pmids\": [\"19594447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single assay system without in vivo validation\", \"Internalization kinetics and recycling not characterized\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic deletion revealed CXCR7 is required for semilunar cardiac valve development, with loss-of-function causing valve stenosis and elevated BMP signaling, establishing the first in vivo developmental requirement.\",\n      \"evidence\": \"Germline and Tie2-Cre endocardial-specific Cxcr7 knockout mice with phospho-Smad1/5/8 immunostaining\",\n      \"pmids\": [\"21246655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BMP pathway link is correlative—direct molecular mechanism connecting CXCR7 to Smad1/5/8 undefined\", \"Ligand mediating valve phenotype unidentified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The C-terminal tail was defined as the molecular determinant controlling CXCR7 constitutive internalization, β-arrestin-2 recruitment, ERK activation, ubiquitination-dependent trafficking, and chemokine scavenging, establishing β-arrestin-biased signaling as the principal transduction mechanism.\",\n      \"evidence\": \"C-tail deletion/point mutants, ubiquitination assays, dynamin inhibition, β-arrestin depletion, ERK phosphorylation, and CXCL12 scavenging assays\",\n      \"pmids\": [\"22300987\", \"22457824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation sites and responsible kinases not yet mapped\", \"Whether β-arrestin is essential or dispensable for internalization unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Genetic epistasis demonstrated that CXCR7 scavenges adrenomedullin in addition to CXCL12, establishing it as a multi-ligand decoy receptor controlling cardiac and lymphatic vascular development through ligand removal rather than signal transduction.\",\n      \"evidence\": \"Cxcr7−/− and Cxcr7−/−;Adm+/− double-knockout rescue in mice with cardiac/lymphatic phenotyping\",\n      \"pmids\": [\"25203207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for adrenomedullin binding versus CXCL12 binding unknown\", \"Whether adrenomedullin scavenging occurs in adult tissues untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"CXCR7 was placed in neural circuit development: endothelial CXCR7 controls plasma CXCL12 gradients for leukocyte migration, while neuronal CXCR7 directs cortical interneuron laminar positioning under Lhx6 transcriptional control, broadening its physiological scope beyond vascular biology.\",\n      \"evidence\": \"CXCR7 knockout mice with plasma CXCL12 ELISA, CXCR7-lacZ reporter immunohistochemistry; ChIP for Lhx6 at CXCR7 enhancer, MGE transplantation rescue in Lhx6−/− mice\",\n      \"pmids\": [\"24116850\", \"24742460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether scavenging or signaling mediates interneuron guidance not dissected\", \"Other transcriptional regulators of CXCR7 in neurons unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"CXCR7 was found to interact with EGFR via β-arrestin-2 scaffolding, enhancing EGFR phosphorylation and ERK signaling in breast cancer, revealing a crosstalk mechanism with receptor tyrosine kinases.\",\n      \"evidence\": \"Proximity ligation assay for CXCR7-EGFR, siRNA knockdown of CXCR7 and β-arrestin-2, phospho-EGFR/ERK Western blots\",\n      \"pmids\": [\"25168820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect interaction not resolved\", \"Whether EGFR crosstalk occurs in non-cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"HHV-8 vCCL2 was identified as a high-affinity viral partial agonist of ACKR3 that triggers β-arrestin recruitment and receptor internalization, demonstrating viral exploitation of the scavenging pathway.\",\n      \"evidence\": \"β-arrestin recruitment, receptor surface quantification, endosomal trafficking, and signaling assays\",\n      \"pmids\": [\"27238288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance during HHV-8 infection not tested\", \"Structural basis for partial agonism unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Phosphorylation-deficient ACKR3 knock-in mice dissociated phosphorylation from β-arrestin dependence in vivo: C-tail phosphorylation is essential for CXCL12 scavenging and interneuron migration, whereas β-arrestin is dispensable, clarifying the minimal signal required for physiological scavenging.\",\n      \"evidence\": \"Phospho-deficient and β-arrestin-KO knock-in mice with in vivo interneuron migration, CXCL12 levels, and CXCR4 degradation assays\",\n      \"pmids\": [\"30726732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase(s) responsible for in vivo phosphorylation not resolved in this study\", \"Alternative internalization pathways not characterized\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ACKR3 was established as a broad-spectrum opioid peptide scavenger, extending its ligand repertoire beyond chemokines and peptide hormones and positioning it as a regulator of endogenous opioid tone.\",\n      \"evidence\": \"Radioligand binding, β-arrestin recruitment, in vitro scavenging assays, ex vivo rat brain pharmacology with ACKR3-selective competitor LIH383\",\n      \"pmids\": [\"32561830\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo behavioral consequences of ACKR3 opioid scavenging not shown\", \"Whether opioid scavenging involves distinct internalization trafficking from chemokine scavenging unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Fine-mapping of the ACKR3 C-tail identified T352/S355 as the critical phosphorylation cluster for β-arrestin-1 recruitment, with GRK2/3 as the responsible kinases, and demonstrated that ACKR3 can internalize via β-arrestin-independent pathways.\",\n      \"evidence\": \"BRET/FRET sensors, phosphosite mutagenesis, GRK co-expression/knockdown in HEK293T cells\",\n      \"pmids\": [\"33799570\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of individual phosphosites not tested\", \"Identity of β-arrestin-independent internalization pathway not determined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Platelet-specific ACKR3 deletion revealed a novel antithrombotic axis: ACKR3 agonism shifts platelet lipid metabolism toward 12-HETrE (from DGLA), which cooperates with prostacyclin receptor/Gαs to activate cAMP/PKA-dependent platelet inhibition, connecting ACKR3 to hemostasis.\",\n      \"evidence\": \"Megakaryocyte/platelet-specific Ackr3 conditional knockout mice, in vivo thrombosis and ischemia-reperfusion models, targeted lipidomics\",\n      \"pmids\": [\"35383158\", \"34905596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ACKR3 engagement alters lipid enzyme activity is unknown\", \"Whether platelet ACKR3 also scavenges chemokines in the hemostatic context not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Comprehensive transducer profiling confirmed ACKR3 is fully uncoupled from all G proteins while engaging β-arrestin predominantly via GRK5/6, and showed that CXCL12-activated ACKR3 and CXCR4 induce distinct β-arrestin conformations, explaining divergent downstream signaling from the same ligand.\",\n      \"evidence\": \"Full transducer-coupling panel, β-arrestin conformation BRET sensors, GRK isoform-specific assays, phosphosite mutagenesis in HEK293 cells\",\n      \"pmids\": [\"37558722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of distinct β-arrestin conformations not solved\", \"Downstream effectors of ACKR3-specific β-arrestin conformation unidentified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ACKR3's multi-ligand promiscuity (chemokines, adrenomedullin, opioids), the identity and regulation of β-arrestin-independent internalization pathways, the mechanism by which ACKR3 reprograms platelet lipid metabolism, and whether ACKR3 opioid scavenging modulates pain or addiction behaviors in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of ACKR3 with a non-chemokine ligand\", \"β-arrestin-independent internalization pathway identity unknown\", \"In vivo behavioral role of opioid scavenging untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 3, 4, 6, 7, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5, 17]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 7, 15]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [3, 14, 15, 16]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 8, 16, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 5, 10, 12]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"complexes\": [\n      \"CXCR4/ACKR3 heterodimer\"\n    ],\n    \"partners\": [\n      \"CXCR4\",\n      \"ARRB2\",\n      \"ARRB1\",\n      \"GRK2\",\n      \"GRK3\",\n      \"GRK5\",\n      \"GRK6\",\n      \"EGFR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}